These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 1735689

  • 1. Phase I study of high dose 5-fluorouracil and high dose Leucovorin with low dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
    Ardalan B, Stridhar K, Reddy R, Benedetto P, Richman S, Waldman S, Morrell L, Feun L, Savaraj N, Livingstone A.
    Int J Radiat Oncol Biol Phys; 1992; 22(3):511-4. PubMed ID: 1735689
    [Abstract] [Full Text] [Related]

  • 2. A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
    Ardalan B, Sridhar KS, Benedetto P, Richman S, Waldman S, Morrell L, Feun L, Savaraj N, Fodor M, Livingstone A.
    Cancer; 1991 Sep 15; 68(6):1242-6. PubMed ID: 1873776
    [Abstract] [Full Text] [Related]

  • 3. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.
    Ardalan B, Singh G, Silberman H.
    J Clin Oncol; 1988 Jun 15; 6(6):1053-8. PubMed ID: 3373260
    [Abstract] [Full Text] [Related]

  • 4. Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas.
    Ardalan B, Ucar A, Reddy R, Livingstone AS, Markoe A, Schwade J, Richman SP, Donofrio K.
    Cancer; 1994 Oct 01; 74(7):1869-73. PubMed ID: 8082092
    [Abstract] [Full Text] [Related]

  • 5. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
    Grem JL, McAtee N, Steinberg SM, Hamilton JM, Murphy RF, Drake J, Chisena T, Balis F, Cysyk R, Arbuck SG.
    Cancer Res; 1993 Oct 15; 53(20):4828-36. PubMed ID: 8402669
    [Abstract] [Full Text] [Related]

  • 6. Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin.
    Seiter K, Kemeny N, Martin D, Schneider A, Williams L, Colofiore J, Sawyer R.
    Cancer; 1993 Mar 01; 71(5):1875-81. PubMed ID: 8448752
    [Abstract] [Full Text] [Related]

  • 7. Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.
    Hageboutros A, Rogatko A, Newman EM, McAleer C, Brennan J, LaCreta FP, Hudes GR, Ozols RF, O'Dwyer PJ.
    Cancer Chemother Pharmacol; 1995 Mar 01; 35(3):205-12. PubMed ID: 7805178
    [Abstract] [Full Text] [Related]

  • 8. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study.
    O'Dwyer PJ, Manola J, Valone FH, Ryan LM, Hines JD, Wadler S, Haller DG, Arbuck SG, Weiner LM, Mayer RJ, Benson AB.
    J Clin Oncol; 2001 May 01; 19(9):2413-21. PubMed ID: 11331320
    [Abstract] [Full Text] [Related]

  • 9. Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
    Fleming RA, Capizzi RL, Muss HB, Smith S, Fernandes DJ, Homesley H, Loggie BW, Case L, Morris R, Russell GB, Richards F.
    Clin Cancer Res; 1996 Jul 01; 2(7):1107-14. PubMed ID: 9816275
    [Abstract] [Full Text] [Related]

  • 10. A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer.
    Jodrell DI, Oster W, Kerr DJ, Canney PA, Yosef H, Steward WP, Kaye SB, Cassidy J.
    Eur J Cancer; 1994 Jul 01; 30A(7):950-5. PubMed ID: 7946590
    [Abstract] [Full Text] [Related]

  • 11. N-(phosphonacetyl)-L-aspartate and calcium leucovorin modulation of fluorouracil administered by constant rate and circadian pattern of infusion over 72 hours in metastatic gastrointestinal adenocarcinoma.
    Grem JL, Yee LK, Schuler B, Hamilton JM, Chen AP, Chabuk C, Grollman F, Grabenc M, Allegra CJ, Takimoto CH.
    Ann Oncol; 2001 Nov 01; 12(11):1581-7. PubMed ID: 11822758
    [Abstract] [Full Text] [Related]

  • 12. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancer.
    Hageboutros A, Hudes GR, Greene F, LaCreta FP, Brennan J, O'Dwyer PJ.
    Invest New Drugs; 1997 Nov 01; 15(2):139-45. PubMed ID: 9220293
    [Abstract] [Full Text] [Related]

  • 13. Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
    Erlichman C, Donehower RC, Speyer JL, Klecker R, Chabner BA.
    J Natl Cancer Inst; 1982 Feb 01; 68(2):227-31. PubMed ID: 6950156
    [Abstract] [Full Text] [Related]

  • 14. A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study.
    Whitehead RP, Benedetti JK, Abbruzzese JL, Ardalan B, Goodwin JW, Balcerzak SP, Samlowski WE, Lenz HJ, Macdonald JS.
    Invest New Drugs; 2004 Aug 01; 22(3):335-41. PubMed ID: 15122082
    [Abstract] [Full Text] [Related]

  • 15. Sequential biochemical modulation of fluorouracil with folinic acid, N-phosphonacetyl-L-aspartic acid, and interferon alfa-2a in advanced colorectal cancer.
    Royce ME, McGarry W, Bready B, Dakhil SR, Belt RJ, Goodwin JW, Gray R, Hoff PM, Winn R, Pazdur R.
    J Clin Oncol; 1999 Oct 01; 17(10):3276-82. PubMed ID: 10506630
    [Abstract] [Full Text] [Related]

  • 16. A phase I trial of combination therapy with continuous-infusion PALA and continuous-infusion 5-FU.
    Weiss GR, Ervin TJ, Meshad MW, Schade D, Branfman AR, Bruni RJ, Chadwick M, Kufe DW.
    Cancer Chemother Pharmacol; 1982 Oct 01; 8(3):301-4. PubMed ID: 7127661
    [Abstract] [Full Text] [Related]

  • 17. Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.
    Rosvold E, Schilder R, Walczak J, DiFino SM, Flynn PJ, Banerjee TK, Heim WJ, Engstrom PF, Ozols RF, O'Dwyer PJ.
    Cancer Chemother Pharmacol; 1992 Oct 01; 29(4):305-8. PubMed ID: 1537077
    [Abstract] [Full Text] [Related]

  • 18. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens.
    O'Dwyer PJ, Hudes GR, Colofiore J, Walczak J, Hoffman J, LaCreta FP, Comis RL, Martin DS, Ozols RF.
    J Natl Cancer Inst; 1991 Sep 04; 83(17):1235-40. PubMed ID: 1714507
    [Abstract] [Full Text] [Related]

  • 19. Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusional 5-fluorouracil in advanced gastric adenocarcinoma. A Southwest Oncology Group study.
    Martino RL, Fleming TR, Morrell LM, Ardalan B, Richman SP, Macdonald JS.
    Invest New Drugs; 1996 Sep 04; 14(4):419-21. PubMed ID: 9157080
    [Abstract] [Full Text] [Related]

  • 20. A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study.
    Whitehead RP, Benedetti JK, Abbruzzese JL, Ardalan B, Williamson S, Gaynor ER, Balcerzak SP, Macdonald JS.
    Invest New Drugs; 2004 Nov 04; 22(4):467-73. PubMed ID: 15292717
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.